Printer Friendly

ISL SHIPS TWO EYE LASER SYSTEMS FOR TREATMENT OF MYOPIA AND HYPEROPIA TO ITALY

 SAN DIEGO, June 24 /PRNewswire/ -- Intelligent Surgical Lasers Inc. (NASDAQ: ISLS) announced today that it has sold and shipped two Eye Laser System upgrades to the University of Rome and the Clinica Villa Tiberta, a private clinic in Rome. Currently using ISL's Model 2001 system, doctors at both sites will upgrade these instruments to the Eye Laser System and begin performing human clinical trials to treat refractive disorders such as nearsightedness, farsightedness and astigmatism. The company has sold a total of three Eye Laser Systems overseas to surgeons in Belgium and now Italy, making ISL the first ophthalmic laser company to sell and ship non-excimer lasers to Europe, according to Heinz R. Gisel, chairman and chief executive officer.
 "Doctors at the University of Rome and the Clinica Villa Tiberta have been very pleased with the new therapeutic clinical results of the Model 2001 system and are looking forward to beginning intrastromal refractive treatment procedures with the Eye Laser System," Gisel said. "The Eye Laser System has preclinically demonstrated its ability to correct refractive disorders without cutting the surface of the eye. This is expected to eliminate many traditional complications including patient pain, corneal hazing and long-term regressions in visual acuity. The clinical data generated at these sites will be extremely valuable as we prepare to begin clinical trials of the system in the U.S."
 ISL filed an Investigational Device Exemption (IDE) for its Eye Laser System with the U.S. Food and Drug Administration in March 1993 to treat myopia (nearsightedness).
 "To assist us in further developing the European market, doctors at the University of Rome and the Clinica Villa Tiberta, along with Dr. Eric Cambie in Gent, Belgium, who was the first ophthalmic surgeon in Europe to purchase an Eye Laser System, will be conducting seminars for ophthalmic surgeons throughout Europe on the use of the Eye Laser for refractive surgeries," Gisel added.
 The Eye Laser is the first non-excimer laser system designed for performing all types of refractive surgeries, as well as other therapeutic surgeries within the eye. The company believes that the accuracy, effectiveness and ease-of-use of the system combine to allow doctors to move these procedures from an expensive operating room environment to a less expensive out-patient environment.
 Intelligent Surgical Lasers Inc. (ISL) is a development-stage company which designs and manufactures innovative, technologically advanced solid-state, picosecond laser systems for the treatment of a broad range of ophthalmic disorders. Many of these disorders are difficult or impossible to treat with current lasers or traditional medical instruments. Founded in 1987, ISL completed a public offering in September 1992.
 -0- 6/24/93
 /CONTACT: Robert J. Feeney, director of Sales and Marketing of ISL, 619-552-6700; or Linda Seaton of Keatinge/Seaton Communications, 619-625-2100, for ISL/
 (ISLS)


CO: Intelligent Surgical Lasers Inc. ST: California IN: MTC SU:

JL-LS -- SD001 -- 5184 06/24/93 09:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:477
Previous Article:HERCULES INC. DIVESTS ITS STOCK IN AUSTRALIAN CHEMICALS HOLDINGS LIMITED
Next Article:PENWEST ANNOUNCES DIVIDEND
Topics:


Related Articles
HAHNEMANN OPHTHALMOLOGIST TESTING NEW LASER EYE SURGERY TECHNIQUE
ISL FILES IDEs FOR NEARSIGHTEDNESS AND A NOVEL GLAUCOMA TREATMENT
ISL REPORTS THIRD QUARTER RESULTS
Take a Closer Look ... Mountain View LCA Laser Vision Center Seeking Patients To Participate in Clinical Trials of Laser Vision Correction For...
LADARVision(R) System Receives FDA Approval for Farsightedness With Astigmatism Correction Using LASIK and for Mixed Astigmatism Using LASIK.
LaserSight Previews AAO Activities And Provides Update.
FDA Approves LaserSight's PMA Supplement for New Manufacturing Facility.
LaserSight Announces Third Quarter Results.
Nidek Files PMA Supplement for Increased Optical Zone.
Nidek Granted U.S. Patent for Cross-Cylinder Ablation; Nidek Develops New Method for Treating Astigmatisms Using LASIK Technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters